Lexicon Pharmaceuticals shares are trading higher. The Company last week announced it will sell Xermelo to GTCR and TerSera Therapeutics for an upfront purchase price of approximately $159 million along with potential milestone payments. NOTE: GTCR issued a press release today detailing the acquisition.